Teva Pharmaceutical Industries Ltd. June 22 announced the launch of its generic version of Eli Lilly and Co.'s Symbyax (olanzapine and fluoxetine) 6 mg/25 mg, 12 mg/25 mg, 6 mg/50 mg, and 12 mg/50 mg capsules.
Symbyax is indicated for the acute treatment of treatment-resistant depression and bipolar I depression in adults, Jerusalem-based Teva said.
The brand product had annual sales of approximately $82 million in the United States, based on IMS sales data.
Learn more about Bloomberg Law or Log In to keep reading:
See Breaking News in Context
Bloomberg Law provides trusted coverage of current events enhanced with legal analysis.
Already a subscriber?
Log in to keep reading or access research tools and resources.